Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Pioglitazone on Pancreatic Steatosis and Bone Health.

Trial Profile

Effect of Pioglitazone on Pancreatic Steatosis and Bone Health.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Insulin resistance
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
  • 24 Oct 2012 Status changed from recruiting to completed.
  • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top